Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

The Psychedelic News Feed reviews major developments from the previous two weeks in the psychedelic field. The episode covers early takeaways from the Psychedelic Healthcare Forum, an FDA-proposed ibogaine trial design submitted for field feedback, and Compass Pathways’ discussion of pricing, product labeling, and a gradual launch strategy. It also reports that New Mexico is nearing the launch of a medical psilocybin program and highlights six potential psychedelic brand names. Together, the topics reflect the field’s movement toward regulated healthcare, including clinical trial planning, commercial preparation, state-level implementation, and the emerging infrastructure needed for potential psychedelic therapy approvals. The supplied description does not provide further detail on the forum discussions, FDA proposal, pricing plans, or New Mexico’s launch timeline.